1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Physician Views: How do Indian oncologists plan to use biosimilar Herceptin?

Scope

Biocon's CANMAb – a biosimilar version of Roche's HER2-positive breast cancer treatment Herceptin (trastuzumab) – is to launch on the Indian market in the first week of February.

Kiran Mazumdar-Shaw –managing director of Biocon – has been quick to speculate that the availability of CANMAb will increase patient access to trastuzumab therapy, primarily due to the cost of Biocon's product, which will sell at a 25 percent discount to the list price of Roche's branded version.

Such claims have caused some consternation among activists, who suggest that the cost of CANMAb will differ immaterially to the discounted price of Herceptin and to the price of a locally branded version of Herceptin – sold as Herclon – that Roche licenses to the domestic player Emcure.

Shaw suggests that the pricing strategy for CANMAb will trigger price cuts by Roche for branded Herceptin, thus expanding market access further. It remains to be seen, however, that if this is the case, whether Biocon can benefit sufficiently from market share gain.

Not only is Herceptin an internationally recognised brand, but Roche has placed significant attention over the past few years on working to increase access to the drug and facilitating improved rates of diagnosis of HER2-positive breast cancer patients.

Furthermore, some question marks over CANMAb remain; the study used for approval was limited in size (132 metastatic breast cancer patients versus a 557-patient study for Celltrion's CT-P6, which has just been approved in South Korea), while Biocon has yet to make any of the clinical data supporting approval of CANMAb publicly available.


Reasons to Buy This Report

With the launch of CANMAb certain to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will mean. Specifically, FirstWord will ask them:

• Which product (Herceptin, Herclon, CANMAb) they expect to be prescribing most in a year's time – assuming the pricing considerations that have been announced at this point?
• By what percentage they expect the trastuzumab market to expand by (i.e. new patients) due to the launch of CANMAb?
• Whether they expect to use CANMAb in metastatic breast cancer patients only (where Biocon trialled the drug) or across the HER2-positive breast cancer treatment paradigm?
• How confident they are in using CANMAb given the relative size of Biocon's study and lack of publicly available clinical data?
• What percentage of treated breast cancer patients they estimate to accurately be diagnosed as being HER2 positive?


Table Of Contents

Physician Views: How do Indian oncologists plan to use biosimilar Herceptin?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Breast Cancer: Analytical Tool

Breast Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" ...


Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Related Market Segments :

Breast Cancer
Targeted Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.